Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer Market

Jazz Pharmaceuticals (JAZZ, Financial), a leading player in the narcolepsy market, is expanding its reach into other markets such as the non-small cell lung cancer (NSCLC) market by preparing a new biliary tract cancer drug; Zanidatamab. Zanidatamab that belongs to the NSCLC market is estimated to be worth $32 billion. Capturing even a modest 5% share could translate into $1.6 billion in additional revenue for Jazz. Considering the company's 2023 revenue of $3.8 billion, this represents a substantial growth ...